Biogen Inc. (BIIB) Stock

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Biogen Inc. is led by CEO Christopher A. Viehbacher, employs 7,605 people, headquartered in Cambridge, US, publicly traded since 1991.

Biogen Inc. (BIIB) stock trades at $202.30 with a market capitalization of $29.87B. The stock is valued at a price-to-earnings (P/E) ratio of 20.80, price-to-book of 1.53, price-to-sales of 2.93. Over the past 52 weeks the stock has ranged between $115.25 and $218.54, and currently trades 7.4% below its 52-week high.

On profitability, Biogen Inc. generates a return on equity (ROE) of 7.70%, return on capital employed of 10.29%, an operating margin of 19.14%, a net profit margin of 13.92%.

In its most recent fiscal year, Biogen Inc. reported annual revenue of $9.8B, net profit of $1.3B, revenue has compounded at -6.1% a year over the last five years, profit at -20.2% a year.

The balance sheet shows a debt-to-equity ratio of 0.35 — a conservative balance sheet with little leverage risk, a current ratio of 2.68, total assets of $29.4B, $3.0B in cash and equivalents.

BIIB has an average daily trading volume of 1,253,616 shares, a beta of 0.18 (less volatile than the overall market).

Official website: www.biogen.com